Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy.

[1]  Harold I Feldman,et al.  Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  Diego R Martin,et al.  Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. , 2008, Radiology.

[3]  Martin R Prince,et al.  Incidence of nephrogenic systemic fibrosis at two large medical centers. , 2008, Radiology.

[4]  M. Panesar,et al.  Clinical improvement of nephrogenic systemic fibrosis after kidney transplantation , 2008, Clinical transplantation.

[5]  A. Molen.  NEPHROGENIC SYSTEMIC FIBROSIS AND THE ROLE OF GADOLINIUM CONTRAST MEDIA , 2008 .

[6]  J. Penfield.  Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents , 2008, Pediatric Nephrology.

[7]  J. Ranville,et al.  Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. , 2008, Kidney international.

[8]  S. Cowper,et al.  Clinical and histological findings in nephrogenic systemic fibrosis. , 2008, European journal of radiology.

[9]  R. Reilly.  Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[10]  P. Marckmann,et al.  Nephrogenic systemic fibrosis: epidemiology update , 2008, Current opinion in nephrology and hypertension.

[11]  A. Kribben,et al.  Contrast media induced nephropathy: definition, incidence, outcome, pathophysiology, risk factors and prevention. , 2008, Minerva Medica.

[12]  H. Thomsen,et al.  High Prevalence of Nephrogenic Systemic Fibrosis in Chronic Renal Failure Patients Exposed to Gadodiamide, a Gadolinium-Containing Magnetic Resonance Contrast Agent , 2008, Investigative radiology.

[13]  S. Cowper,et al.  NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: Early Recognition and Treatment , 2008, Seminars in dialysis.

[14]  Jane O. Schell,et al.  NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Treatment of Nephrogenic Systemic Fibrosis: Limited Options but Hope for the Future , 2008, Seminars in dialysis.

[15]  R. Rodby.  NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Dialytic Therapies to Prevent NSF Following Gadolinium Exposure in High‐Risk Patients , 2008, Seminars in dialysis.

[16]  S. Punwani,et al.  NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: Non‐Gadolinium Options for the Imaging of CKD/ESRD Patients , 2008, Seminars in dialysis.

[17]  R. Reilly,et al.  What nephrologists need to know about gadolinium , 2007, Nature Clinical Practice Nephrology.

[18]  L. Skov,et al.  Case-control study of gadodiamide-related nephrogenic systemic fibrosis. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  R. Woolson,et al.  Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[20]  W. Eubank,et al.  Steady‐state free precession MRA of the renal arteries: Breath‐hold and navigator‐gated techniques vs. CE‐MRA , 2007, Journal of magnetic resonance imaging : JMRI.

[21]  Sudhir V. Shah,et al.  New insights into nephrogenic systemic fibrosis. , 2007, Journal of the American Society of Nephrology : JASN.

[22]  L. Chibnik,et al.  Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. , 2007, Arthritis and rheumatism.

[23]  M. Reiser,et al.  Nephrogene systemische Fibrose (NSF) – Implikationen für die Radiologie , 2007, Der Radiologe.

[24]  H. Thomsen,et al.  Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis? , 2007, Acta radiologica.

[25]  Z. Endre.  Nephrogenic systemic fibrosis: is any contrast safe in renal failure? , 2007, Internal medicine journal.

[26]  John Gosbee,et al.  ACR guidance document for safe MR practices: 2007. , 2007, AJR. American journal of roentgenology.

[27]  M. Goyen,et al.  Nephrogenic systemic fibrosis is not exclusively associated with gadodiamide , 2007, European Radiology.

[28]  K. Ballen.  Targeting the stem cell niche: squeezing blood from bones , 2007, Bone Marrow Transplantation.

[29]  A. Djamali,et al.  Nephrogenic systemic fibrosis: risk factors and incidence estimation. , 2007, Radiology.

[30]  S. Cowper,et al.  Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[31]  E. Fleck,et al.  Comparison of different MRI techniques for the assessment of thoracic aortic pathology: 3D contrast enhanced MR angiography, turbo spin echo and balanced steady state free precession , 2007, The International Journal of Cardiovascular Imaging.

[32]  S. Morcos.  Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? , 2007, The British journal of radiology.

[33]  V. Runge,et al.  Nephrogenic Systemic Fibrosis: A Review of 6 Cases Temporally Related to Gadodiamide Injection (Omniscan) , 2007, Investigative radiology.

[34]  M. Lucia,et al.  A case of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis , 2007, Nature Clinical Practice Nephrology.

[35]  Gerald A Kirk,et al.  Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. , 2007, AJR. American journal of roentgenology.

[36]  S. Textor,et al.  Comparison between gadolinium and iodine contrast for percutaneous intervention in atherosclerotic renal artery stenosis: clinical outcomes. , 2007, Nephrology, Dialysis and Transplantation.

[37]  M. Port,et al.  Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review , 2006, Fundamental & clinical pharmacology.

[38]  H. Thomsen.  Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide , 2006, European Radiology.

[39]  M. Pittelkow,et al.  Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. , 2006, Annals of internal medicine.

[40]  Yoshiaki Tanaka,et al.  Dialyzability of gadodiamide in hemodialysis patients , 2006, Radiation Medicine.

[41]  S. Cowper,et al.  Nephrogenic systemic fibrosis: An update , 2006, Current rheumatology reports.

[42]  T. Grobner.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[43]  S. Cowper.  Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[44]  R. Elenitsas,et al.  Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema , 2005, Journal of cutaneous pathology.

[45]  S. Jimenez,et al.  Involvement of skeletal muscle in dialysis‐associated systemic fibrosis (nephrogenic fibrosing dermopathy) , 2004, Muscle & nerve.

[46]  P. Leboit,et al.  Nephrogenic fibrosing dermopathy: two pediatric cases. , 2003, The Journal of pediatrics.

[47]  C. Heeschen,et al.  Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. , 2003, Blood.

[48]  R. Bucala,et al.  Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. , 2003, The American Journal of dermatopathology.

[49]  M. Miyazaki,et al.  Peripheral MR angiography: separation of arteries from veins with flow-spoiled gradient pulses in electrocardiography-triggered three-dimensional half-Fourier fast spin-echo imaging. , 2003, Radiology.

[50]  R. Swartz,et al.  Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. , 2003, The American journal of medicine.

[51]  F. Maes,et al.  Improved visualization of coronary arteries using a new three-dimensional submillimeter MR coronary angiography sequence with balanced gradients. , 2002, AJR. American journal of roentgenology.

[52]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[53]  R. Poveda,et al.  Goodpasture syndrome during the course of a Schönlein-Henoch purpura. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[54]  F. S. Pereles,et al.  Thoracic aortic dissection and aneurysm: evaluation with nonenhanced true FISP MR angiography in less than 4 minutes. , 2002, Radiology.

[55]  P. Leboit,et al.  Nephrogenic Fibrosing Dermopathy , 2001, The American Journal of dermatopathology.

[56]  P. Leboit,et al.  Scleromyxoedema-like cutaneous diseases in renal-dialysis patients , 2000, The Lancet.

[57]  S. Swan,et al.  Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. , 1999, Investigative radiology.

[58]  H. Thomsen,et al.  Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. , 1998, Academic radiology.

[59]  M. Hunter,et al.  Volume-activated, gadolinium-sensitive whole-cell currents in single proximal cells of frog kidney , 1994, Pflügers Archiv.

[60]  S. Cowper,et al.  Nephrogenic systemic fibrosis: an overview. , 2008, Journal of the American College of Radiology : JACR.

[61]  F. Artunc,et al.  Nephrogene systemische Fibrose , 2008, Deutsche medizinische Wochenschrift.

[62]  A. Rosenkranz,et al.  Conventional or Gadolinium containing contrast media: the choice between acute renal failure or Nephrogenic Systemic Fibrosis? , 2007, Wiener klinische Wochenschrift.

[63]  J. Zic,et al.  Gadolinium deposition in nephrogenic fibrosing dermopathy. , 2007, Journal of the American Academy of Dermatology.

[64]  S. Cowper,et al.  Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. , 2007, Journal of the American Academy of Dermatology.

[65]  N. Liégeois,et al.  Clinical and pathologic features of nephrogenic fibrosing dermopathy: a report of two cases. , 2003, Journal of the American Academy of Dermatology.

[66]  D. Cohen,et al.  Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). , 2003, Journal of the American Academy of Dermatology.